Stoughton, MA – According to filings with the U.S. Securities and Exchange Commission, Beeken BioMedical is raising $6,330,531.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Richard Kendall played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Beeken BioMedical

Beeken Biomedical is a medical device company dedicated to the advancement of bleeding control. The company is focused on the development, licensing and commercialization of wound care products. It’s innovative Hemafiber Technology enables first responders and hospital patient care providers to rapidly control bleeding by using the NuStat products to establish hemostasis and stability to patients.

To learn more about Beeken BioMedical, visit http://www.beekenbiomedical.com/

Contact:
Richard Kendall, Chief Executive Officer
888-497-7376
https://www.linkedin.com/in/richard-kendall-1a52b711/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved